Model Costs: Cost-Utility Analysis of a Respiratory Diagnostic Test for COPD

A 9.5 KB Excel file contains model-based cost-utility analysis results for a diagnostic test in chronic obstructive pulmonary disease (COPD) management. The study by Raymond Oppong, published on figshare in April 2026, evaluates the Biofire Film Array Respiratory Panel RP 2.1+ test over a 40-year healthcare perspective. Results indicate the test is cost-saving, with potential annual savings estimated between £118 million and £18.6 billion.

Use Cases

• Validate cost-effectiveness model parameters based on the described literature review and expert opinion inputs.
• Analyze the impact of antimicrobial resistance (AMR) cost adjustments based on the two described accounting approaches.
• Compare cost and quality-adjusted life year (QALY) outcomes between diagnostic strategies based on the reported £2762.40 cost difference and 0.03 QALY difference.
• Assess the probability of cost-effectiveness for a new diagnostic test based on the reported 70% chance.

Strengths

• Model parameters were informed by a targeted literature review and expert opinions.
• The analysis incorporates two distinct approaches to account for antimicrobial resistance (AMR) costs.
• Results include specific numerical outcomes: a £2762.40 cost difference, a 0.03 QALY difference, and a 70% probability of cost-effectiveness.

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download.
• The dataset is very small (9.5 KB), indicating it likely contains summary model outputs rather than raw or extensive data.

Provenance

Source

Raymond Oppong via figshare.

Collection Method

Model-based cost-utility analysis informed by literature review and expert opinion.

Time Range

Model horizon is 40 years.

Freshness

Last updated 2026-04 27 17:26:46.

Geography

null